Membro della SCNAT

La SSPT promuove e sostiene gli interessi della farmacologia e della tossicologia in Svizzera. Organizza convegni scientifici e rappresenta i suoi membri nelle associazioni nazionali.

Immagine: Naturmotive – stock-adobe.com
pharmacology image
pharmacology image

ABOUT US

The SSPT was founded in 1965 and is a scientific society. The purpose of the society is to promote and support all interests of Pharmacology and Toxicology in Switzerland (Bye-Laws).

The SSPT currently constitutes the umbrella organisation of the following four member societies:

  • Swiss Society of Experimental Pharmacology (SSEP),
  • Swiss Society of Clinical Pharmacology and Toxicology (SSCPT),
  • Swiss Society of Toxicology (SST),
  • Swiss Society of Pharmaceutical Medicine (SGPM).

The SSPT organizes scientific meetings of general interest for all associated societies. The SSPT represents the field of Pharmacology and Toxicology in Switzerland within national societies and associations including Life Sciences Switzerland (LS2) and Swiss Academy of Sciences (SCNAT).

***

TRAVEL GRANTS

The SSPT provides travel grants to post-graduates in Biomedical Sciences in training, supporting travel to international scientific conferences. The travel grants are awarded twice a year: May 15 and October 15. Applications are welcomed (whenever possible please send your application electronically):

***

INTERESTED TO LEARN MORE ABOUT PHARMACOLOGY IN SWITZERLAND ?

See: Special Issue "Country in focus: Pharmacology in Switzerland"

Link

***

BECOME A EUROPEAN CERTIFIED PHARMACOLOGIST (EuCP)

See:

  • This homepage: https://swisspharmtox.ch/de/education
  • EPHAR homepage: https://www.ephar.org/eucp/index.html

***

ATTEND THE SSPT SPRING MEETING 2022

The SSPT SPRING MEETING 2022 ENTITLED "OUTBREAK COVID-19" WILL TAKE PLACE ON APRIL 28, 2022 AT THE INSELSPITAL BERN (FORMAT: F2F)

CME credit points provided for participation in the meeting:

  • Swiss Society of Pharmaceutical Medicine (SSPM): 8 credits
  • Swiss Society of Clinical Pharmacology and Toxicology (SSCPT): 8 credits

Prize Winners of the SSPT Spring Meeting 2022

NIBR Prize

Ophélie Molton, Department of Biomedical Sciences, University of Lausanne (poster presentation)

Determination of the Ca2+ binding sites of acid-sensing ion channel 1a (ASIC1a). Ophélie Molton, Olivier Bignucolo, Stephan Kellenberger, Department of Biomedical Sciences, University of Lausanne, 1011 Lausanne (abstract No 03)

***

Darko Stojkov, Institute of Pharmacology, University of Bern (poster presentation)

Empagliflozin for treating neutropenia/neutrophil dysfunction in infants with glycogen storage disorder Ib under the age of 1 year. Darko Stojkov 1,2, Hans-Uwe Simon 1,3,4,5, Maria Veiga-da Cunha 6,7, Saskia B. Wortmann 8,9, Matthias Gautschi 10, 1Institute of Pharmacology, University of Bern, Bern, Switzerland, 2Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany, 3Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia, 4Laboratory of Molecular Immunology, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia, 5Institute of Biochemistry, Medical School Brandenburg, Neuruppin, Germany, 6Groupe de Recherches Metaboliques, de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium, 7Walloon Excellence in Lifesciences and Biotechnology, Brussels, Belgium, 8University Children’s Hospital, Paracelsus Medical University (PMU), Salzburg, Austria, 9Radboud Center for Mitochondrial Medicine, Department of Pediatrics, Amalia Children’s Hospital, Radboud University Medical Center, Nijmegen, The Netherlands, 10Division of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics and Institute of Clinical Chemistry, University Hospital Bern, Inselspital, Bern, Switzerland (abstract No 19)

***

SSPM Prize

Perparim Limani, University Hospital Zurich (oral presentation):

Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. Marcel A Schneider1,2, Michael Linecker1,2, Ralph Fritsch1,3, Urs J Muehlematter4, Daniel Stocker4, Bernhard Pestalozzi1,3, Panagiotis Samaras5, Alexander Jetter6, Philipp Kron1,2, Henrik Petrowsky1,2, Claude Nicolau7, Jean-Marie Lehn8, Bostjan Humar1,2, Rolf Graf1,2, Pierre-Alain Clavien1,2, Perparim Limani1,2, 1Swiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland,2Department of Surgery & Transplantation, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland 3Department of Oncology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland, 4Institute of Interventional and Diagnostic Radiology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland, 5Oncology Center, Hirslanden Hospital Zurich, Witellikerstrasse 40, Zurich, Switzerland, 6Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland, 7Friedman School of Nutrition Science and Policy, Tufts University, 150 Harrison Ave, Boston, MA, USA,8 Institut de Science et d'Ingénierie Supramoléculaires (ISIS), Université de Strasbourg, 8 allée Gaspard Monge, Strasbourg, France (abstract No 02)

CONGRATULATIONS TO THE WINNERS !

Contatto

Società Svizzera di Farmacologia e Tossicologia (SSPT)
c/o PD Dr. Gabriele Weitz-Schmidt
AlloCyte Pharmaceuticals AG
Hochbergerstrasse 60C
4057 Basilea